Autoimmune Diseases, Crohn Disease, Inflammatory Bowel Diseases, Ulcerative Colitis
Conditions
Brief summary
The goal of this clinical trial is to test the ATH-063 drug (single and multiple doses) in Healthy Subjects. The clinical trial aims to evaluate the below. 1. Safety of the drug 2. Tolerability of the drug 3. Pharmacokinetics (PK) (how the human body affects the drug) 4. Pharmacodynamics (PD) (how the drug affects the human body) This will be a single center, Phase 1, First-In-Human, Randomized, Double-Blind (neither the subjects nor the experimenters know which subjects are in the test and control groups), Placebo (a look-alike substance that contains no active drug) - Controlled Study.
Detailed description
Primary Objective of this study will be to evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses (SAD/MAD) in healthy subjects. This is a single center, Phase 1, Randomized, Double-blind, Placebo controlled, sequential SAD/MAD study, with a food-effect arm. The study will be divided into three parts: * SAD cohorts * MAD cohorts * Food-effect (FE) cohort MAD and FE cohorts will be dosed in parallel after the completion of the SAD Cohorts SAD Part: 1. Consist of at least 4 cohorts (1 cohort per dose level). 2. Each cohort will include approximately 8 participants (6 participants receiving the active and 2 participants receiving the placebo). 3. A staggered dosing schedule will be used for dosing of each cohort (under fasting conditions) MAD Part: 1. Consist of up to 4 cohorts (1 cohort per dose level). 2. Each cohort will include approximately 8 participants (6 participants receiving the active and 2 participants receiving the placebo). 3. The cohorts will be dosed sequentially in an ascending fashion. 4. The dose of MAD cohorts is dependent on the available safety, tolerability, and PK data from the SAD part and available safety, tolerability, and PK data from dosed MAD cohorts. Food-effect Part: 1. Approximately twelve (12) participants will be randomized in a 1:1 ratio to one of two treatment sequences (fast-fed/fed-fast) with 6 participants per treatment sequence. 2. The selection of the dose to be administered in the food effect part will depend on the results of the SAD part following the review of safety, tolerability and PK data of the SAD cohorts.
Interventions
DRUGATH-063
12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
DRUGPlacebo
Identical capsule to the drug without the active ingredient.
Sponsors
Syneos Health
Athos Therapeutics Australia Pty Ltd
Athos Therapeutics Inc
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The study will be double-blinded. The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (ATH-063 or placebo).
Intervention model description
Cohorts (4 each) within the SAD and MAD part will be dosed sequentially in an ascending fashion. MAD cohorts and FE cohort will be dosed in parallel after the completion of the SAD Cohorts.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening) or social smoker (smokers with 1-5 cigarettes a week), AND with a negative urine cotinine test at check-in, ≥18 and ≤55 years of age, with BMI \>18.5 and \<32.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females and a maximum weight of 120 kg. 2. Healthy as defined by: 1. the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration. 2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. A history of migraines, childhood asthma, or non-hospitalized depression would not be considered clinically significant. 3. Female participants of non-childbearing potential must be: 1. post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented follicle-stimulating hormone (FSH) levels ≥ 40 mIU/mL; or 2. surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or tubal ligation) at least 3 months prior to dosing. 4. Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study as detailed in section 8.1. 5. Able to understand the study procedures and provide signed informed consent to participate in the study.
Exclusion criteria
1. Any clinically significant abnormal finding at physical examination. 2. Clinically significant abnormal laboratory test results or positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody, at screening. 3. Positive pregnancy test or lactating female subject 4. Positive urine drug screen, urine cotinine test, or alcohol breath test (one repeat is allowed). 5. History of significant allergic reactions (e.g., anaphylactic reaction, hypersensitivity, angioedema) to any drug. 6. Clinically significant ECG abnormalities or vital signs abnormalities (systolic BP lower than 90 or over 160 mmHg, diastolic BP lower than 50 or over 95 mmHg, HR less than 45 or over 100 bpm, or RR less than 12 or over 22 bpm) at screening. 7. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening. 8. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 45 mL of distilled alcohol 40%). Low risk level = 10 unites per week for men and women. 9. Use of medications for the timeframes specified below, with the exception of hormonal contraceptives and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety (e.g., topical drug products without significant systemic absorption): 1. depot injection or implant within 3 months prior to the first dosing; 2. live attenuated vaccines within 1 month prior to the first dosing; 3. any drug known to induce or inhibit hepatic drug metabolism, including St. John's wort, within 30 days prior to the first dosing; 4. prescription medications within 14 days prior to the first dosing; 5. any other vaccine, including COVID-19 vaccine, within 14 days prior to the first dosing; 6. over-the-counter (OTC) medications and natural health products (including herbal remedies such as, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to the first dosing, with the exception of the occasional use of paracetamol (up to 2 g daily). 10. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days or 5 x T1/2 whichever is longer prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days or 5 x T1/2 whichever is longer prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration. 11. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing. 12. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of ATH-063 following oral administration of single and multiple ascending doses in healthy participants. | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | Number of participants with serious and other non-serious adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic assessment 8 | SAD: Up to 15 ± 1 day, FE: Up to 14 ± 1 day | Cl/F (Oral Clearance) |
| Pharmacokinetic assessment 14 | MAD: Up to 24 ± 1 day | Tmax ss (Time to steady state Cmax) |
| Pharmacokinetic assessment 15 | MAD: Up to 24 ± 1 day | Cmin ss (Minimum drug concentration at steady-state) |
| Pharmacokinetic assessment 16 | MAD: Up to 24 ± 1 day | Vz ss/F (Apparent volume of distribution at steady state) |
| Pharmacokinetic assessment 17 | FE: Up to 14 ± 1 day | Tlag (Lag time) |
| Pharmacokinetic assessment 1 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | AUC0-t (Area under the plasma concentration-time curve) |
| Pharmacokinetic assessment 2 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | AUC0-inf (AUC curve to infinite time) |
| Pharmacokinetic assessment 3 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | Cmax (Maximum plasma concentration) |
| Pharmacokinetic assessment 4 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | Tmax (Time to maximum plasma concentration (Cmax) |
| Pharmacokinetic assessment 5 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | Residual area |
| Pharmacokinetic assessment 6 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | T½ el (Half Life) |
| Pharmacokinetic assessment 7 | SAD: Up to 15 ± 1 day, MAD: Up to 24 ± 1 day, FE: Up to 14 ± 1 day | Kel (Elimination rate constant) |
| Pharmacokinetic assessment 9 | MAD: Up to 24 ± 1 day | Clss/F (Oral Clearance-steady state) |
| Pharmacokinetic assessment 10 | SAD: Up to 15 ± 1 day, FE: Up to 14 ± 1 day | Vz/F (Apparent volume of distribution) |
| Pharmacokinetic assessment 11 | MAD: Up to 24 ± 1 day | AUC0-24 (area under the plasma concentration-time curve over the last 24-h dosing interval) |
| Pharmacokinetic assessment 12 | MAD: Up to 24 ± 1 day | AUC0-tau (area under the curve to the end of the dosing period) |
| Pharmacokinetic assessment 13 | MAD: Up to 24 ± 1 day | Cmax ss (Maximum plasma concentration at steady state) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamic assessment 3 | MAD: Up to 24 ± 1 day | change from baseline in plasma proteomic signature |
| Pharmacodynamic assessment 4 | MAD: Up to 24 ± 1 day | change from baseline in stool microbiome signature |
| Pharmacodynamic assessment 2 | MAD: Up to 24 ± 1 day | change from baseline in T-regulatory cells H3K9 methylation status |
| Pharmacodynamic assessment 1 | MAD: Up to 24 ± 1 day | change from baseline in T-regulatory cells immunophenotype |
Countries
Australia
Outcome results
None listed